FDA Approval of Vepdegestrant: A New ESR1-Targeted Option for Advanced Breast Cancer

A treatment decision now follows an ESR1 result

The approval reported August 15, 2026, turns an acquired resistance alteration into a treatment-selection biomarker. Vepdegestrant is indicated for adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer whose tumors harbor an ESR1 mutation and whose disease has progressed after endocrine therapy, according to the regulatory decision indexed in PubMed.

The practical change is specific. ESR1 testing is no longer only explanatory or prognostic in this setting; a positive result can establish eligibility for an approved targeted endocrine treatment. Testing should be timed when the result could alter the next line of therapy, particularly after progression on an aromatase inhibitor-based regimen and a cyclin-dependent kinase 4 and 6 inhibitor.

ESR1 mutations are often acquired under the selective pressure of estrogen deprivation. Many occur in the estrogen receptor ligand-binding domain and can stabilize the receptor in an active conformation, allowing estrogen receptor signaling to continue despite low estrogen concentrations. They are therefore uncommon in untreated primary tumors but become more frequent in metastatic disease exposed to aromatase inhibitors.

A negative result must be interpreted in context. Mutation abundance can change during treatment, and circulating tumor DNA assays depend on adequate tumor DNA shedding. When a plasma result is negative or uninformative but suspicion remains high, tissue testing may provide additional information if a suitable specimen can be obtained. Eligibility ultimately depends on the FDA-approved label and an appropriate validated test.

What the comparative trial showed

The regulatory decision was supported by VERITAC-2, a randomized phase 3 trial comparing oral vepdegestrant with intramuscular fulvestrant. The trial enrolled 624 patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer previously treated with endocrine therapy and a CDK4/6 inhibitor. Patients were randomly assigned to vepdegestrant or fulvestrant, and the primary efficacy analyses included the ESR1-mutated population and the overall intention-to-treat population.

In the ESR1-mutated subgroup, vepdegestrant reduced the hazard of progression or death by 43% relative to fulvestrant. Median progression-free survival was 5.0 months with vepdegestrant and 2.1 months with fulvestrant, corresponding to a hazard ratio of 0.57 with a 95% confidence interval of 0.42 to 0.77. The reported difference was statistically significant.

The overall trial population did not show a statistically significant progression-free survival improvement. Median progression-free survival was 3.7 months with vepdegestrant and 3.6 months with fulvestrant; the hazard ratio was 0.83, with a 95% confidence interval of 0.68 to 1.02. This divergence is central to the approval: the treatment effect was concentrated in cancers carrying ESR1 mutations rather than established across all estrogen receptor-positive disease.

Follow-up at the primary analysis was relatively short, at approximately seven months, and overall survival data were not mature. The progression-free survival comparison was randomized, supporting a causal interpretation of the difference between assigned treatments within the studied population. Subgroup findings outside the prespecified ESR1-mutated analysis should be treated more cautiously.

How PROTAC degradation differs from endocrine blockade

Vepdegestrant is a proteolysis-targeting chimera, or PROTAC. It is a bifunctional molecule: one end binds the estrogen receptor, while the other recruits an E3 ubiquitin ligase. Bringing those proteins together forms a ternary complex that promotes receptor ubiquitination. The cell’s proteasome then recognizes and degrades the tagged estrogen receptor.

This is an event-driven process rather than solely an occupancy-driven one. After facilitating degradation, a PROTAC molecule may dissociate and participate in another degradation cycle. The aim is to reduce the amount of estrogen receptor protein available to sustain transcription, including altered receptors encoded by ESR1-mutated tumors.

That mechanism differs from the principal approaches used in conventional endocrine therapy. Aromatase inhibitors reduce estrogen synthesis but do not directly eliminate the receptor; ESR1 ligand-binding domain mutations can allow signaling to continue despite estrogen deprivation. Selective estrogen receptor modulators, such as tamoxifen, bind the receptor and alter its activity in a tissue-dependent manner. Conventional selective estrogen receptor degraders, including fulvestrant, antagonize the receptor and promote its destabilization, but they do not recruit an E3 ligase through a PROTAC complex.

The mechanistic distinction should not be translated into a general claim that PROTACs are intrinsically superior to other endocrine therapies. Clinical value depends on comparative outcomes, safety, disease biology and the treatment setting. In VERITAC-2, the advantage over fulvestrant was demonstrated in the ESR1-mutated population, not conclusively in the full randomized cohort.

How the approval changes practice

The decision creates a clear branch point after endocrine resistance develops. For a patient with estrogen receptor-positive, HER2-negative advanced disease who meets the label’s prior-treatment criteria, an ESR1 mutation supports consideration of vepdegestrant. Without a qualifying mutation, this approval does not provide a basis for its use.

Circulating tumor DNA is attractive because ESR1 mutations may be heterogeneous, newly acquired and easier to detect in plasma than through a biopsy of a single metastatic site. Testing close to progression may better capture current tumor biology than relying on archival primary-tumor tissue collected before endocrine exposure. Laboratories and clinicians must still use an assay appropriate to the regulatory indication and understand its analytic limitations.

Treatment selection remains broader than one biomarker. Disease tempo, metastatic sites, symptoms, prior toxicities, co-alterations, available endocrine combinations and the need for chemotherapy all affect sequencing. The trial compared vepdegestrant with fulvestrant; it did not establish superiority over every other therapy available for endocrine-resistant breast cancer.

Important limits and unanswered issues

The phase 3 evidence directly applies to patients resembling those enrolled: estrogen receptor-positive, HER2-negative advanced disease previously exposed to endocrine therapy and a CDK4/6 inhibitor. Generalizability is less certain for earlier treatment, prior use of other oral estrogen receptor degraders, extensive chemotherapy exposure, rapidly progressive visceral disease or patient groups underrepresented in the trial.

Progression-free survival was the principal efficacy measure, while overall survival remained immature at the primary analysis. Longer follow-up is needed to determine whether delaying progression translates into longer survival or a durable quality-of-life advantage. Resistance mechanisms after vepdegestrant and the value of combinations with other targeted agents also remain unsettled.

The trial was sponsored by the drug’s developers, which is relevant when interpreting design, analysis and reporting. Randomization and an active comparator strengthen the evidence, but independent follow-up and postmarketing safety data will be important as use expands beyond a controlled trial.

Questions clinicians ask

Who should undergo ESR1 mutation testing?

Testing is most consequential for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer whose disease has progressed during or after endocrine therapy. The result should be available when another endocrine line is being selected, because a qualifying mutation can establish eligibility for vepdegestrant under the FDA label.

Is plasma testing sufficient for treatment selection?

A validated circulating tumor DNA assay can detect acquired ESR1 mutations without another invasive biopsy and may capture mutations from several metastatic sites. A negative plasma result is not always definitive, however, particularly when little tumor DNA is being shed; tissue testing may be considered when clinically feasible and the result would change management.

Does vepdegestrant replace fulvestrant for all ER-positive disease?

No. The statistically significant progression-free survival benefit over fulvestrant was demonstrated in the prespecified ESR1-mutated population. The overall randomized population did not meet the corresponding statistical threshold, so the evidence and approval support biomarker-selected use rather than routine substitution across all estrogen receptor-positive advanced breast cancers.

Does an ESR1 mutation make chemotherapy necessary?

Not by itself. An ESR1 mutation indicates resistance to estrogen-deprivation strategies and creates an endocrine treatment option through vepdegestrant, but it does not determine the entire sequence of care. Symptoms, visceral involvement, pace of progression, previous therapies and other actionable tumor features remain important when deciding between endocrine-based treatment and chemotherapy.

References

1. FDA Approval Summary: Vepdegestrant for ESR1-Mutated Advanced Breast Cancer — PubMed, National Library of Medicine, 2026 2. A Study of Vepdegestrant (ARV-471) Versus Fulvestrant in Participants With ER+/HER2- Advanced Breast Cancer (VERITAC-2) — ClinicalTrials.gov, National Library of Medicine, 2022 3. List of Cleared or Approved Companion Diagnostic Devices — U.S. Food and Drug Administration, 2026